A new Validated RP-HPLC Method for simultaneous quantification of Raloxifene and Curcumin

Abstract

Raloxifene (RLX) and Curcumin (CUR) are used for the treatment of breast cancer. Its combination is chosen because of their synergistic therapeutic potential, which helps to reduce drug-related toxicities while increasing therapeutic efficacy. A simple, sensitive, accurate and specific technique for determining retention time by employing reverse-phase high-performance liquid chromatography for simultaneous estimation of both the drugs was developed as well validated for the analysis on their particular wavelength. The separation was performed on an RP C-18 Column (EC 250/4 neucleosil 100-10) with column dimensions 250mm x 4.60mm, 10mM using mobile phase Potassium dihydrogen phosphate: acetonitrile (pH 3.0 with Orthophosphoric acid) in the ratio of 20:80 v/v and flow rate of 1.0min/mL. The specificity, linearity range, accuracy, sensitivity, robustness, precision, and ruggedness of the method were all determined. The analyte's peaks were found to be well resolved, and two different RTs for RLX and CUR were observed. Over a concentration range of 1-5g/ml, RLX and CUR calibration curves were shown to be linear. All of the technique validation criteria were within acceptable limits. For inter- and intra-day precision, the relative standard deviation (%RSD) was found to be <2%.